Literature DB >> 33813728

Exosomal miR-21-5p contributes to ovarian cancer progression by regulating CDK6.

Jian Cao1, Yuan Zhang2, Juan Mu3, Dazhen Yang1, Xiaoyan Gu4, Jing Zhang5.   

Abstract

Ovarian cancer is a predominant gynecologic malignancy and correlated with high mortality and severe morbidity. Exosomal microRNAs (miRNAs) play crucial roles in various processes during the progression of ovarian cancer, such as cell proliferation, apoptosis, and invasion. However, the function of exosomal miR-21-5p in ovarian cancer is still unknown. Here, we found that miR-21-5p was upregulated in ovarian cancer tissues, plasma exosomes of ovarian cancer patients, and exosomes from ovarian cancer cells. MiR-21-5p was incorporated in the exosomes from the ovarian cancer cells. In addition, 5-ethynyl-2'-deoxyuridine (Edu), a marker of cancer cell proliferation, was enhanced by miR-21-5p mimic while reduced by miR-21-5p inhibitor in ovarian cancer cells. MiR-21-5p mimic could increase, but miR-21-5p inhibitor could decrease the migration and invasion of cancer cells. Ovarian cancer cell apoptosis was induced by miR-21-5p inhibitor. Moreover, miR-21-5p inhibitor could up-regulate the expression of pro-apoptotic cleaved caspase3 and Bax while downregulate the expression of anti-apoptotic Bcl2 in the cells. Exosomal miR-21-5p inhibited the expression of cyclin-dependent kinase 6 (CDK6) by targeting its 3'-untranslated region (3'-UTR) at both the mRNA and protein levels. Tumorigenicity analysis in nude mice revealed that exosomal miR-21-5p could increase tumor volume, size, and weight of ovarian cancer in vivo. Besides, miR-21-5p targeted CDK6 in tumor tissues of nude mice. In conclusion, exosomal miR-21-5p contributes to the progression of ovarian cancer by regulating CDK6. Our findings will provide novel insights into the mechanism of exosomal miR-21-5p in the development of ovarian cancer. Exosomal miR-21-5p may serve as a potential target for the therapy of ovarian cancer.

Entities:  

Keywords:  CDK6; Exosome; MiR-21-5p; Ovarian cancer; Progression

Year:  2021        PMID: 33813728     DOI: 10.1007/s13577-021-00522-2

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  48 in total

1.  Central adiposity as a major risk factor of ovarian cancer.

Authors:  Laetitia Delort; Fabrice Kwiatkowski; Nassera Chalabi; Samir Satih; Yves-Jean Bignon; Dominique J Bernard-Gallon
Journal:  Anticancer Res       Date:  2009-12       Impact factor: 2.480

Review 2.  Epidemiology of epithelial ovarian cancer.

Authors:  Penelope M Webb; Susan J Jordan
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2016-10-03       Impact factor: 5.237

3.  Family history of breast cancer as a risk factor for ovarian cancer in a prospective study.

Authors:  Neely Kazerouni; Mark H Greene; James V Lacey; Pamela J Mink; Catherine Schairer
Journal:  Cancer       Date:  2006-09-01       Impact factor: 6.860

4.  Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results.

Authors:  Gooitzen M van Dam; George Themelis; Lucia M A Crane; Niels J Harlaar; Rick G Pleijhuis; Wendy Kelder; Athanasios Sarantopoulos; Johannes S de Jong; Henriette J G Arts; Ate G J van der Zee; Joost Bart; Philip S Low; Vasilis Ntziachristos
Journal:  Nat Med       Date:  2011-09-18       Impact factor: 53.440

5.  Identification of molecular biomarkers for ovarian cancer using computational approaches.

Authors:  H Lalremmawia; Basant K Tiwary
Journal:  Carcinogenesis       Date:  2019-07-06       Impact factor: 4.944

6.  CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells.

Authors:  M-Q Gao; Y-P Choi; S Kang; J H Youn; N-H Cho
Journal:  Oncogene       Date:  2010-03-01       Impact factor: 9.867

Review 7.  MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.

Authors:  Rajesha Rupaimoole; Frank J Slack
Journal:  Nat Rev Drug Discov       Date:  2017-02-17       Impact factor: 84.694

Review 8.  MicroRNA.

Authors:  Thomas X Lu; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2017-10-23       Impact factor: 10.793

9.  Commentary: Mendelian randomization analysis identifies circulating vitamin D as a causal risk factor for ovarian cancer.

Authors:  Caroline J Bull; James Yarmolinsky; Kaitlin H Wade
Journal:  Int J Epidemiol       Date:  2016-10       Impact factor: 7.196

Review 10.  Role of Exosomal Noncoding RNAs in Lung Carcinogenesis.

Authors:  Tao Sun; Bill Kalionis; Guoying Lv; Shijin Xia; Wen Gao
Journal:  Biomed Res Int       Date:  2015-10-25       Impact factor: 3.411

View more
  10 in total

1.  Clinical role of miR-421 as a novel biomarker in diagnosis of gastric cancer patients: A meta-analysis.

Authors:  Yingying Xu; Guiping Wang; Wenqing Hu; Songbing He; Dandan Li; Ping Chen; Jinjie Zhang; Yongshun Gao; Duonan Yu; Liang Zong
Journal:  Medicine (Baltimore)       Date:  2022-05-13       Impact factor: 1.817

2.  Long non-coding RNA CASC7 suppresses malignant behaviors of breast cancer by regulating miR-21-5p/FASLG axis.

Authors:  Genjin Wang; Peng Duan; Feng Liu; Zhengkuo Wei
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

3.  Ropivacaine represses the proliferation, invasion, and migration of glioblastoma via modulating the microRNA-21-5p/KAT8 regulatory NSL complex subunit 2 axis.

Authors:  Zexiang Deng; Yanping Jian; Hongwei Cai
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

4.  Exosomes and ferroptosis: roles in tumour regulation and new cancer therapies.

Authors:  Yixin Shi; Bingrun Qiu; Linyang Huang; Jie Lin; Yiling Li; Yiting Ze; Chenglong Huang; Yang Yao
Journal:  PeerJ       Date:  2022-04-26       Impact factor: 3.061

5.  DNA methyltransferase 3 beta regulates promoter methylation of microRNA-149 to augment esophageal squamous cell carcinoma development through the ring finger protein 2/Wnt/β-catenin axis.

Authors:  Junfeng Yang; Quan Zhang; Pu Zhao; Tong Qiao; Zhikun Cao; Fei Gao; Mengbo Liu; Sen Wu
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

Review 6.  Roles of exosomes as drug delivery systems in cancer immunotherapy: a mini-review.

Authors:  Zhen Fang; Yixuan Ding; Zhigang Xue; Peijuan Li; Jia Li; Fei Li
Journal:  Discov Oncol       Date:  2022-08-13

Review 7.  Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies.

Authors:  Lindsey A McAlarnen; Prachi Gupta; Reena Singh; Sunila Pradeep; Pradeep Chaluvally-Raghavan
Journal:  Mol Ther Oncolytics       Date:  2022-08-05       Impact factor: 6.311

Review 8.  Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs.

Authors:  Arsinoe C Thomaidou; Panagiota Batsaki; Maria Adamaki; Maria Goulielmaki; Constantin N Baxevanis; Vassilis Zoumpourlis; Sotirios P Fortis
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

Review 9.  Advances in Exosomes as Diagnostic and Therapeutic Biomarkers for Gynaecological Malignancies.

Authors:  Mengdan Miao; Yifei Miao; Yanping Zhu; Junnan Wang; Huaijun Zhou
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

Review 10.  The Role of miRNA in Ovarian Cancer: an Overview.

Authors:  Lihui Zhao; Xiaolei Liang; Liyan Wang; Xuehong Zhang
Journal:  Reprod Sci       Date:  2022-01-01       Impact factor: 2.924

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.